Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MedicosBiotech Wins CES 2025 Innovation Award in Digital Health - Medical Product Outsourcing
OEM News

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

The company's Cure Silk combines advanced AI with spider silk protein-based therapeutic patches.

Cure Silk is effective at treating stage 3–4 pressure ulcers and grade 5–6 diabetic foot ulcers. Photo: PRNewswire.

MedicosBiotech has received the CES Innovation Award in the Digital Health category at this year’s Consumer Electronics Show (Las Vegas, through Jan. 11). The award honors excellence in innovation, technology, and design, spotlighting MedicosBiotech’s chronic wound care solution, Cure Silk.

Cure Silk improves chronic wound treatment by combining advanced artificial intelligence (AI) with spider silk protein-based therapeutic patches. This solution empowers users through the Cure Silk App, which uses a smartphone camera to capture and analyze wound images. With AI-driven diagnostics, the app identifies wound types and severity, offering tailored treatment recommendations. This user-friendly technology ensures that anyone, even without medical expertise, can manage chronic wounds at home.

At the core of Cure Silk is its spider silk protein-based patch, a breakthrough innovation led by MedicosBiotech CEO Dr. Wonmin Yoo. This patch is highly effective for treating stage 3–4 pressure ulcers and grade 5–6 diabetic foot ulcers—conditions that have long lacked effective solutions. MedicosBiotech anticipates South Korea’s Ministry of Food and Drug Safety (MFDS) Class II medical device approval for Cure Silk early this year.

Spider silk protein, known for its strength, elasticity, and biocompatibility, has been used in wound care for more than 2,000 years but was previously hindered by production challenges. MedicosBiotech’s synthetic biology advancements have made scalable production possible, unlocking the full potential of this material.

“This award recognizes MedicosBiotech’s innovative fusion of AI and biotechnology,” MedicosBiotech Chief Operating Officer Soon Cheol Daniel Kim said. “Cure Silk is an affordable, easy-to-use solution that enhances access to chronic wound care, contributing to a more inclusive global healthcare system.”

MedicosBiotech develops sustainable, bio-based solutions for wound care, skincare, and hair restoration. Key innovations from the Korean firm include: MCB-WH, A fast-acting wound healer; MCB-Graft, a solution for hair loss prevention and regrowth; and MCB-SpiderSilk, vegan, eco-friendly spider silk for skincare and medical use.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters